‘Confounding’ Sarepta Could Tumble 75%, Leerink Says

Barron's Andrew Bary is out with a positive piece on Sarepta Therapeutics ( SRPT ) this morning, arguing that the stock, which has tumbled 68% so far this year, could triple if its treatment for Duchenne muscular dystrophy gets fast-track approval . Leerink's Joseph Schwartz and team, however, don't believe the reward outweighs the risk. They explain why: